BZYR
Price
$0.03
Change
-$0.01 (-25.00%)
Updated
Aug 29 closing price
Capitalization
3.42M
CRNX
Price
$35.62
Change
+$1.37 (+4.00%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
3.23B
62 days until earnings call
Interact to see
Advertisement

BZYR vs CRNX

Header iconBZYR vs CRNX Comparison
Open Charts BZYR vs CRNXBanner chart's image
Burzynski Research Institute
Price$0.03
Change-$0.01 (-25.00%)
Volume$500
Capitalization3.42M
Crinetics Pharmaceuticals
Price$35.62
Change+$1.37 (+4.00%)
Volume$43.45K
Capitalization3.23B
BZYR vs CRNX Comparison Chart in %
Loading...
BZYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BZYR vs. CRNX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BZYR is a Hold and CRNX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (BZYR: $0.03 vs. CRNX: $34.25)
Brand notoriety: BZYR and CRNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BZYR: 1% vs. CRNX: 143%
Market capitalization -- BZYR: $3.42M vs. CRNX: $3.23B
BZYR [@Biotechnology] is valued at $3.42M. CRNX’s [@Biotechnology] market capitalization is $3.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BZYR’s FA Score shows that 0 FA rating(s) are green whileCRNX’s FA Score has 0 green FA rating(s).

  • BZYR’s FA Score: 0 green, 5 red.
  • CRNX’s FA Score: 0 green, 5 red.
According to our system of comparison, CRNX is a better buy in the long-term than BZYR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BZYR’s TA Score shows that 4 TA indicator(s) are bullish while CRNX’s TA Score has 5 bullish TA indicator(s).

  • BZYR’s TA Score: 4 bullish, 5 bearish.
  • CRNX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than BZYR.

Price Growth

BZYR (@Biotechnology) experienced а -35.00% price change this week, while CRNX (@Biotechnology) price change was +11.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.23B) has a higher market cap than BZYR($3.42M). BZYR YTD gains are higher at: -16.129 vs. CRNX (-33.014). BZYR has higher annual earnings (EBITDA): -1.35M vs. CRNX (-419.62M). CRNX has more cash in the bank: 1.2B vs. BZYR (821). CRNX has higher revenues than BZYR: CRNX (1.39M) vs BZYR (0).
BZYRCRNXBZYR / CRNX
Capitalization3.42M3.23B0%
EBITDA-1.35M-419.62M0%
Gain YTD-16.129-33.01449%
P/E RatioN/AN/A-
Revenue01.39M-
Total Cash8211.2B0%
Total DebtN/A49.9M-
FUNDAMENTALS RATINGS
BZYR vs CRNX: Fundamental Ratings
BZYR
CRNX
OUTLOOK RATING
1..100
3313
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
86
Overvalued
PROFIT vs RISK RATING
1..100
10064
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
9349
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5039

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (86) in the Pharmaceuticals Major industry is in the same range as BZYR (99) in the null industry. This means that CRNX’s stock grew similarly to BZYR’s over the last 12 months.

CRNX's Profit vs Risk Rating (64) in the Pharmaceuticals Major industry is somewhat better than the same rating for BZYR (100) in the null industry. This means that CRNX’s stock grew somewhat faster than BZYR’s over the last 12 months.

CRNX's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as BZYR (100) in the null industry. This means that CRNX’s stock grew similarly to BZYR’s over the last 12 months.

CRNX's Price Growth Rating (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for BZYR (93) in the null industry. This means that CRNX’s stock grew somewhat faster than BZYR’s over the last 12 months.

CRNX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as BZYR (100) in the null industry. This means that CRNX’s stock grew similarly to BZYR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BZYRCRNX
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 19 days ago
67%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
N/A
Bearish Trend 17 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
BZYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APDLX15.520.03
+0.19%
Artisan Value Advisor
CSUCX24.100.04
+0.17%
Cohen & Steers Global Infrastructure C
GCECX18.26N/A
N/A
AB Global Core Equity C
VFPIX18.34N/A
N/A
Private Capital Management Value I
GQGPX16.95N/A
N/A
GQG Partners Emerging Markets Equity Inv

BZYR and

Correlation & Price change

A.I.dvisor tells us that BZYR and DWTX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BZYR and DWTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BZYR
1D Price
Change %
BZYR100%
N/A
DWTX - BZYR
29%
Poorly correlated
+1.52%
CRNX - BZYR
21%
Poorly correlated
-1.15%
RENB - BZYR
20%
Poorly correlated
-4.09%
BVNRY - BZYR
10%
Poorly correlated
+0.23%
BIXT - BZYR
1%
Poorly correlated
+2.60%
More

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-1.15%
XNCR - CRNX
63%
Loosely correlated
+0.48%
RVMD - CRNX
58%
Loosely correlated
-2.06%
IDYA - CRNX
57%
Loosely correlated
+0.27%
NRIX - CRNX
56%
Loosely correlated
-3.59%
SYRE - CRNX
56%
Loosely correlated
+1.07%
More